Research ExplorerPublicationsIntensive dose-dense compared with conventionally scheduled ...

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.

Standard

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. / Untch, Michael; Möbus, Volker; Kuhn, Walther; Muck, Bernd Rudolph; Thomssen, Christoph; Bauerfeind, Ingo; Harbeck, Nadia; Werner, Christoph; Lebeau, Annette; Schneeweiss, Andreas; Kahlert, Stephen; von Koch, Franz; Petry, Karl Ulrich; Wallwiener, Diethelm; Kreienberg, Rolf; Albert, Ute-Susann; Lück, Hans-Joachim; Hinke, Axel; Jänicke, Fritz; Konecny, Gottfried E.

In: J CLIN ONCOL, Vol. 27, No. 18, 18, 2009, p. 2938-2945.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Untch, M, Möbus, V, Kuhn, W, Muck, BR, Thomssen, C, Bauerfeind, I, Harbeck, N, Werner, C, Lebeau, A, Schneeweiss, A, Kahlert, S, von Koch, F, Petry, KU, Wallwiener, D, Kreienberg, R, Albert, U-S, Lück, H-J, Hinke, A, Jänicke, F & Konecny, GE 2009, 'Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.', J CLIN ONCOL, vol. 27, no. 18, 18, pp. 2938-2945. <http://www.ncbi.nlm.nih.gov/pubmed/19364964?dopt=Citation>

APA

Untch, M., Möbus, V., Kuhn, W., Muck, B. R., Thomssen, C., Bauerfeind, I., Harbeck, N., Werner, C., Lebeau, A., Schneeweiss, A., Kahlert, S., von Koch, F., Petry, K. U., Wallwiener, D., Kreienberg, R., Albert, U-S., Lück, H-J., Hinke, A., Jänicke, F., & Konecny, G. E. (2009). Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J CLIN ONCOL, 27(18), 2938-2945. [18]. http://www.ncbi.nlm.nih.gov/pubmed/19364964?dopt=Citation

Vancouver

Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J CLIN ONCOL. 2009;27(18):2938-2945. 18.

Bibtex

@article{89cd3e50dc7f4baba5aac026c3643bef,
title = "Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.",
abstract = "PURPOSE: To compare preoperative intense dose-dense (IDD) chemotherapy with conventionally scheduled preoperative chemotherapy in high-risk primary breast cancer (BC). PATIENTS AND METHODS: In this randomized phase III trial a total of 668 eligible primary BC patients stratified for tumors > or = 3 cm (n = 567) or inflammatory BC (n = 101) were randomly assigned to receive concurrent preoperative epirubicin/paclitaxel every 3 weeks or dose-dense and dose-escalated sequential epirubicin followed by paclitaxel every 2 weeks. All patients received three cycles of cyclophosphamide, methotrexate, and fluorouracil chemotherapy after surgery. RESULTS: IDD treatment significantly improved pathologic complete response rate (18% v 10%; odds ratio [OR] 1.89; P = .008), disease-free survival (DFS; hazard ratio [HR], 0.71; P = .011), and overall survival (OS; HR, 0.83; P = .041) compared to epirubicin/paclitaxel. Patients with inflammatory BC had a particularly poor prognosis and did not appear to benefit from IDD therapy in this trial (DFS HR, 1.10; P = .739; OS HR, 1.25; P = .544). In contrast, patients with noninflammatory BC significantly benefited from IDD treatment (DFS HR, 0.65, P = .005; OS HR, 0.77, P = .013). Treatment effects in multivariate analysis were significant for noninflammatory BC (DFS HR, 0.65, P = .015; OS HR, 0.79, P = .034), but not for all patients (DFS HR, 0.76; P = .088; OS HR, 0.82; P = .059). IDD therapy was associated with significantly more nonhematologic toxicities, anemia, and thrombocytopenia, but with similar neutropenia and infection rates. CONCLUSION: Our results support the efficacy and short-term safety of IDD as preoperative chemotherapy. IDD was less well tolerated compared to standard treatment, but improved clinical outcomes in patients with noninflammatory high-risk primary BC.",
author = "Michael Untch and Volker M{\"o}bus and Walther Kuhn and Muck, {Bernd Rudolph} and Christoph Thomssen and Ingo Bauerfeind and Nadia Harbeck and Christoph Werner and Annette Lebeau and Andreas Schneeweiss and Stephen Kahlert and {von Koch}, Franz and Petry, {Karl Ulrich} and Diethelm Wallwiener and Rolf Kreienberg and Ute-Susann Albert and Hans-Joachim L{\"u}ck and Axel Hinke and Fritz J{\"a}nicke and Konecny, {Gottfried E}",
year = "2009",
language = "Deutsch",
volume = "27",
pages = "2938--2945",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

RIS

TY - JOUR

T1 - Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.

AU - Untch, Michael

AU - Möbus, Volker

AU - Kuhn, Walther

AU - Muck, Bernd Rudolph

AU - Thomssen, Christoph

AU - Bauerfeind, Ingo

AU - Harbeck, Nadia

AU - Werner, Christoph

AU - Lebeau, Annette

AU - Schneeweiss, Andreas

AU - Kahlert, Stephen

AU - von Koch, Franz

AU - Petry, Karl Ulrich

AU - Wallwiener, Diethelm

AU - Kreienberg, Rolf

AU - Albert, Ute-Susann

AU - Lück, Hans-Joachim

AU - Hinke, Axel

AU - Jänicke, Fritz

AU - Konecny, Gottfried E

PY - 2009

Y1 - 2009

N2 - PURPOSE: To compare preoperative intense dose-dense (IDD) chemotherapy with conventionally scheduled preoperative chemotherapy in high-risk primary breast cancer (BC). PATIENTS AND METHODS: In this randomized phase III trial a total of 668 eligible primary BC patients stratified for tumors > or = 3 cm (n = 567) or inflammatory BC (n = 101) were randomly assigned to receive concurrent preoperative epirubicin/paclitaxel every 3 weeks or dose-dense and dose-escalated sequential epirubicin followed by paclitaxel every 2 weeks. All patients received three cycles of cyclophosphamide, methotrexate, and fluorouracil chemotherapy after surgery. RESULTS: IDD treatment significantly improved pathologic complete response rate (18% v 10%; odds ratio [OR] 1.89; P = .008), disease-free survival (DFS; hazard ratio [HR], 0.71; P = .011), and overall survival (OS; HR, 0.83; P = .041) compared to epirubicin/paclitaxel. Patients with inflammatory BC had a particularly poor prognosis and did not appear to benefit from IDD therapy in this trial (DFS HR, 1.10; P = .739; OS HR, 1.25; P = .544). In contrast, patients with noninflammatory BC significantly benefited from IDD treatment (DFS HR, 0.65, P = .005; OS HR, 0.77, P = .013). Treatment effects in multivariate analysis were significant for noninflammatory BC (DFS HR, 0.65, P = .015; OS HR, 0.79, P = .034), but not for all patients (DFS HR, 0.76; P = .088; OS HR, 0.82; P = .059). IDD therapy was associated with significantly more nonhematologic toxicities, anemia, and thrombocytopenia, but with similar neutropenia and infection rates. CONCLUSION: Our results support the efficacy and short-term safety of IDD as preoperative chemotherapy. IDD was less well tolerated compared to standard treatment, but improved clinical outcomes in patients with noninflammatory high-risk primary BC.

AB - PURPOSE: To compare preoperative intense dose-dense (IDD) chemotherapy with conventionally scheduled preoperative chemotherapy in high-risk primary breast cancer (BC). PATIENTS AND METHODS: In this randomized phase III trial a total of 668 eligible primary BC patients stratified for tumors > or = 3 cm (n = 567) or inflammatory BC (n = 101) were randomly assigned to receive concurrent preoperative epirubicin/paclitaxel every 3 weeks or dose-dense and dose-escalated sequential epirubicin followed by paclitaxel every 2 weeks. All patients received three cycles of cyclophosphamide, methotrexate, and fluorouracil chemotherapy after surgery. RESULTS: IDD treatment significantly improved pathologic complete response rate (18% v 10%; odds ratio [OR] 1.89; P = .008), disease-free survival (DFS; hazard ratio [HR], 0.71; P = .011), and overall survival (OS; HR, 0.83; P = .041) compared to epirubicin/paclitaxel. Patients with inflammatory BC had a particularly poor prognosis and did not appear to benefit from IDD therapy in this trial (DFS HR, 1.10; P = .739; OS HR, 1.25; P = .544). In contrast, patients with noninflammatory BC significantly benefited from IDD treatment (DFS HR, 0.65, P = .005; OS HR, 0.77, P = .013). Treatment effects in multivariate analysis were significant for noninflammatory BC (DFS HR, 0.65, P = .015; OS HR, 0.79, P = .034), but not for all patients (DFS HR, 0.76; P = .088; OS HR, 0.82; P = .059). IDD therapy was associated with significantly more nonhematologic toxicities, anemia, and thrombocytopenia, but with similar neutropenia and infection rates. CONCLUSION: Our results support the efficacy and short-term safety of IDD as preoperative chemotherapy. IDD was less well tolerated compared to standard treatment, but improved clinical outcomes in patients with noninflammatory high-risk primary BC.

M3 - SCORING: Zeitschriftenaufsatz

VL - 27

SP - 2938

EP - 2945

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 18

M1 - 18

ER -